1. Nanoparticle therapy has potential to reprogram the immune system in type 1 diabetes
COUR Pharmaceuticals is about to begin a phase 1b/2a study to assess a therapy for type 1 diabetes that prevents islet cell destruction and triggers a T cell response.
Read more
2. Cuts to indirect research costs to impact type 1 diabetes
Aaron J. Kowalski, Ph.D., CEO of Breakthrough T1D, spoke with Managed Healthcare Executive about the possible impacts of the NIH’s cuts to indirect research funding.
Read more
3. Diabetes Association updates guidelines for type 1 diabetes
The updated guidelines from the American Diabetes Association emphasize the use of antibody-based screening for type 1 diabetes and recommend that physicians discuss potential use of Tzield, a monoclonal antibody approved to delay the onset of the symptoms of the disease.
Read more
4. New type of stem cell transplant shows promise in type 1 diabetes
Sana Biotechnology’s hypoimmune platform enables it to make a series of genetic modifications to cells, rendering the cells invisible to a patient’s immune system.
Read more
5. Phase 3 trial of Vertex’s islet cell therapy for type 1 diabetes under way
Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if approved, would be the second cell therapy for type 1 diabetes.
Read more